Van Ellis advises biopharmaceutical, medical device, and digital health companies across the full range of transactions that arise during the life cycle of a product, including major collaborations, licensing arrangements, and a variety of commercial agreements. Mr. Ellis has more than 25 years of experience representing both multinational and early stage life sciences companies on matters ranging from billion dollar global collaborations to daily commercial and operational matters. He also advises life sciences companies in connection with initial public offerings and mergers and acquisitions.
Mr. Ellis serves as one of the leaders of Covington’s multidisciplinary Medical Device Industry Group, and has broad experience with strategic alliances and transactions for the development and commercialization of FDA regulated medical devices, including agreements for research and development, clinical trials, licensing of technologies and components, manufacturing and supply, and distribution and marketing. He has advised companies on a wide range of medical device technologies, ranging from implanted devices such as heart pumps, ocular lenses, drug-eluting stents, and intra-uterine devices; to wearables such as artificial limbs, advanced contact lenses, and neuro-stimulation devices; and to imaging devices, surgical instruments, and disease treatment technologies.
Mr. Ellis is also one of the transactional leaders of Covington’s multidisciplinary Digital Health Industry Group. He has advised biopharmaceutical, high tech, and MedTech companies on a wide range of digital health products, tools, and services, including, cloud-based AI for use in diagnosing and preparing treatment plans for a disease; supercomputing-based AI as a tool in drug development; smartphone apps for patient use in managing disease states; wearable therapeutic devices connected to smartphone apps; and advanced algorithms for use by hospitals in identifying high risk patients.
